{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-060702","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.045778+00:00","generated_at":"2026-06-18T11:45:35.427029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verrica reports FY 2022 net loss $24.5M; VP-102 PDUFA set for July 23, 2023","bullets":["Net loss of $24.5M ($0.72/share) for FY 2022 vs $35.1M ($1.30/share) in FY 2021.","Collaboration revenue of $9.0M in FY 2022, down from $12.0M in FY 2021.","Cash and equivalents $34.3M at Dec 31, 2022; raised $32.5M gross in Feb 2023 secondary offering.","FDA assigned PDUFA date of July 23, 2023 for VP-102 NDA for molluscum contagiosum.","VP-315 Phase 2 Part 2 dosing expected to begin in Q2 2023 for basal cell carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-060702","json":"https://secwatch.observer/filing/0001193125-23-060702.json","markdown":"https://secwatch.observer/filing/0001193125-23-060702.md","text":"https://secwatch.observer/filing/0001193125-23-060702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/0001193125-23-060702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/d474665d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:45:35.427029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e29a66891a4966c4dff6ceab0f2336869b2c32b3","claim":"Verrica Pharmaceuticals Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 6, 2023, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523060702/0001193125-23-060702-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}